Leonard Livschitz
Analyst · Needham.
Yes. So thank you, Mayank. Let me take the first part of it, and I'm sure Anil will be happy to give you a little bit more -- few thoughts.
First of all, as you understand right now, we don't give a very clear 2021 guidance at this point. It doesn't mean we don't have an idea what's going on. Basically, there are a lot of variables. And as you know, 2020 was not a very usual year. We experienced a very significant turnaround in Q3, both on revenue and profitability, but we started with a very low bar and being a ambitious CEO, I want to see much more. I want to see to grow above pre-COVID levels and to grow above-pre-COVID levels on the performance, including profitability. So we need to do a lot of more aggressive stuff, but it was a great quarter.
So let me tell you a little bit of my sense. First of all, we anticipate that on the revenue side, we're going to reach pre-COVID level by the end of Q4. What's going to happen in early 2021 in terms of the bookings and the new contracts? Obviously, this is a little bit super mature to talk about it in early November. Even in the best times of the year, people start talking about budgeting somewhere during late November, early December, that's where we're firming up. So a little bit easier on the tech, little bit more complex on other segments. But I would say that overall it shapes up positive, but it's very hard to give you the quantitative numbers.
In terms of the growth, 20%, 25%. I believe the world is more prepared for COVID fluctuation and increase during the fall and winter season that we were caught last year. So it may or may not be as complicated from impact on the industry. But I'm not a professional person in the medical field, so I can't really tell. If we assume there is no significant impact on the business in the future, I think this 20%, 25% growth is easily doable for us next year. But at this point, it is very difficult to say because, again, there are variances.
But I'm looking very optimistic both in Q4 and the next year from the diversification of our plan. As you think about it, our turnaround was not because of the guys paused the budget and brought back to [ us ], but we're expanding the breadth of the company. So while I see positive, let's wait for the next call and we can give you much more color for 2021. Does it make sense?